Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, alt...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/819 |
| _version_ | 1797626414192656384 |
|---|---|
| author | Anna Diana Francesca Carlino Elisena Franzese Olga Oikonomidou Carmen Criscitiello Ferdinando De Vita Fortunato Ciardiello Michele Orditura |
| author_facet | Anna Diana Francesca Carlino Elisena Franzese Olga Oikonomidou Carmen Criscitiello Ferdinando De Vita Fortunato Ciardiello Michele Orditura |
| author_sort | Anna Diana |
| collection | DOAJ |
| description | Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population. |
| first_indexed | 2024-03-11T10:10:02Z |
| format | Article |
| id | doaj.art-9a12effdc7a64d3c96836bd0bf12f152 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T10:10:02Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9a12effdc7a64d3c96836bd0bf12f1522023-11-16T14:34:34ZengMDPI AGCancers2072-66942020-03-0112481910.3390/cancers12040819Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic LandscapesAnna Diana0Francesca Carlino1Elisena Franzese2Olga Oikonomidou3Carmen Criscitiello4Ferdinando De Vita5Fortunato Ciardiello6Michele Orditura7Division of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, ItalyDivision of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, ItalyDivision of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, ItalyCancer Research UK, Edinburgh Centre, MRC Institute Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UKIEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDivision of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, ItalyDivision of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, ItalyDivision of Medical Oncology, Department of Precision Medicine, School of Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, ItalyTriple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.https://www.mdpi.com/2072-6694/12/4/819triple negative breast cancerneo-(adjuvant)biomarkersPARP inhibitorsimmunotherapy |
| spellingShingle | Anna Diana Francesca Carlino Elisena Franzese Olga Oikonomidou Carmen Criscitiello Ferdinando De Vita Fortunato Ciardiello Michele Orditura Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes Cancers triple negative breast cancer neo-(adjuvant) biomarkers PARP inhibitors immunotherapy |
| title | Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes |
| title_full | Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes |
| title_fullStr | Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes |
| title_full_unstemmed | Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes |
| title_short | Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes |
| title_sort | early triple negative breast cancer conventional treatment and emerging therapeutic landscapes |
| topic | triple negative breast cancer neo-(adjuvant) biomarkers PARP inhibitors immunotherapy |
| url | https://www.mdpi.com/2072-6694/12/4/819 |
| work_keys_str_mv | AT annadiana earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT francescacarlino earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT elisenafranzese earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT olgaoikonomidou earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT carmencriscitiello earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT ferdinandodevita earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT fortunatociardiello earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes AT micheleorditura earlytriplenegativebreastcancerconventionaltreatmentandemergingtherapeuticlandscapes |